Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
Summary
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions
Why It Matters
This announcement reflects ongoing developments in the technology sector that may impact enterprise IT strategy, consumer technology adoption, or industry competitive dynamics.
Note
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.